ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Ferrous fumarate: Drug information

Ferrous fumarate: Drug information
(For additional information see "Ferrous fumarate: Patient drug information" and see "Ferrous fumarate: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Ferretts [OTC];
  • Ferrimin 150 [OTC];
  • Hemocyte [OTC] [DSC]
Pharmacologic Category
  • Iron Preparations
Dosing: Adult

Note: Dosage expression: Dose is expressed in terms of elemental iron; ferrous fumarate contains 33% elemental iron per mg of mineral salt (eg, each 325 mg tablet contains ~106 mg elemental iron). Formulation: Enteric-coated and slow/sustained-release preparations are generally not preferred due to poor absorption (Hershko 2014; Liu 2012). Route of administration: IV iron replacement is preferred over oral replacement in several clinical situations (eg, poor GI absorption, lack of response to or poor tolerability of oral iron, chronic kidney disease, active inflammatory bowel disease, cancer, chronic or extensive blood loss) (Auerbach 2021).

Iron deficiency or iron-deficiency anemia

Iron deficiency or iron-deficiency anemia: Oral: 29 to 150 mg of elemental iron (1 tablet) once every other day or on Monday, Wednesday, and Friday. Note: Daily dosing has been shown to result in reduced absorption but may be reasonable in some individuals to improve adherence (Auerbach 2021; Stoffel 2017; Stoffel 2020).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Older Adult

Lower doses (15 to 50 mg elemental iron/day) may have similar efficacy and less GI adverse events (eg, nausea, constipation) as compared to higher doses (eg, 150 mg elemental iron/day) (Rimon 2005).

Dosing: Pediatric

(For additional information see "Ferrous fumarate: Pediatric drug information")

Note: Doses expressed as elemental iron. Ferrous fumarate contains 33% elemental iron.

Iron deficiency, prevention

Iron deficiency, prevention:

AAP recommendations:

Infants ≥4 months (exclusively fed human milk or human milk provides >50% of nutrition without iron fortified food): Oral: 1 mg elemental iron/kg/day; supplementation should be continued until sufficient iron is provided in complementary foods (AAP [Baker 2010]).

WHO recommendations:

Areas where anemia prevalence is ≥40%:

Infants ≥6 months and Children <2 years: Oral: 10 to 12.5 mg elemental iron daily for 3 consecutive months in a year (WHO 2016b).

Children 2 to <5 years: Oral: 30 mg elemental iron daily for 3 consecutive months in a year (WHO 2016b).

Children 5 to 12 years: Oral: 30 to 60 mg elemental iron daily for 3 consecutive months in a year (WHO 2016b).

Adolescent menstruating patients (nonpregnant patients of reproductive potential): Oral: 30 to 60 mg elemental iron daily for 3 consecutive months in a year (WHO 2016a).

Areas where anemia prevalence 20% to <40%: Weekly intermittent dosing:

Children 2 to <5 years: Oral: 25 mg elemental iron once weekly for 3 consecutive months, then alternating 3 months off supplementation, 3 months on supplementation (WHO 2011).

Children 5 to 12 years: Oral: 45 mg elemental iron once weekly for 3 consecutive months, then alternating 3 months off supplementation, 3 months on supplementation (WHO 2011).

Iron deficiency, treatment

Iron deficiency, treatment: Infants, Children, and Adolescents: Oral: Initial: 3 mg elemental iron/kg/day as a single daily dose (Kazal 2002; Oski 1993; Powers 2017; Reeves 1985) up to 60 to 120 mg elemental iron once daily (AAP [Kleinman 2019]); higher doses may be needed in select patients; dosage range: 3 to 6 mg elemental iron/kg/day in 1 to 3 divided doses; usual maximum daily dose: 150 to 200 mg elemental iron/day (ASPEN [Corkins 2015]; Kliegman 2020; Zlotkin 2001); once-daily administration may be preferred for ease of administration and adherence (Zlotkin 2001). Studies in iron-depleted adults suggest that iron absorption may be improved by less frequent dosing (alternate-day dosing, or once daily versus multiple daily doses) (Moretti 2015; Stoffel 2017).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not defined.

>10%: Gastrointestinal: Constipation, darkening of stools, nausea, stomach cramps, vomiting

1% to 10%:

Gastrointestinal: Dental discoloration, diarrhea, heartburn

Genitourinary: Urine discoloration

<1%, postmarketing, and/or case reports: Local irritation

Contraindications

Hemochromatosis, hemolytic anemia.

Warnings/Precautions

Disease-related concerns:

• Gastrointestinal disease: Avoid in patients with peptic ulcer, enteritis, or ulcerative colitis.

• Porphyria: Use with caution in patients with porphyria.

Special populations:

• Blood transfusion recipients: Avoid in patients receiving frequent blood transfusions.

• Older adult: Anemia in the elderly is often caused by “anemia of chronic disease” or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin >50 ng/mL and a decreased total iron binding capacity. Hence, the “anemia of chronic disease” is not secondary to iron deficiency but the inability of the reticuloendothelial system to reclaim available iron stores.

• Pediatric: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.

• Premature infants: Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished.

Dosage form specific issues:

• Oral iron formulations: Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012).

Other warnings/precautions:

• Duration of therapy: Administration of iron for >6 months should be avoided except in patients with continuous bleeding or menorrhagia.

Warnings: Additional Pediatric Considerations

Consider all iron sources when evaluating the dose of iron, including combination products, infant formulas, and liquid nutritional supplements.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Ferretts: 325 mg (106 mg elemental iron) [scored]

Ferrimin 150: Elemental iron 150 mg

Hemocyte: 324 mg (106 mg elemental iron) [DSC]

Generic: 324 mg (106 mg elemental iron), 324 mg (106 mg elemental iron), Elemental iron 29 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Ferrimin 150 Oral)

150 mg (per each): $0.13

Tablets (Ferrocite Oral)

324 mg (per each): $0.22

Tablets (Ferrous Fumarate Oral)

324 (106 Fe) mg (per each): $0.35

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Administer with a full glass of water. Do not lie down for 30 minutes after administration.

Administration: Pediatric

Oral: Administer with water or juice prior to breakfast and/or between meals for maximum absorption (CDC 1998; Kliegman 2020; Oski 1993); may administer with food if GI upset occurs; do not administer with milk or milk products.

Use: Labeled Indications

Iron deficiency or iron-deficiency anemia: Prevention and treatment of iron-deficiency anemias.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha-Lipoic Acid: Iron Preparations may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Preparations. Management: Separate administration of alpha-lipoic acid from that of any iron-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral iron-containing products at lunch or dinner. Risk D: Consider therapy modification

Antacids: May decrease the absorption of Iron Preparations. Management: No action is likely necessary for the majority of patients who only use antacids intermittently or occasionally. Consider separating doses of oral iron and antacids in patients who require chronic use of both agents and monitor for reduced iron efficacy. Risk D: Consider therapy modification

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Risk X: Avoid combination

Bictegravir: Iron Preparations may decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron preparations under fed conditions, but coadministration with or 2 hours after an iron preparation is not recommended under fasting conditions. Risk D: Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Risk D: Consider therapy modification

Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir. Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir. Risk D: Consider therapy modification

Cefdinir: Iron Preparations may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron when possible. Separate doses by at least 2 hours if combined. Iron-containing infant formulas do not appear alter cefdinir pharmacokinetics, but red-appearing, non-bloody stools may develop when combined. Risk D: Consider therapy modification

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Risk D: Consider therapy modification

Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations. Risk X: Avoid combination

Dolutegravir: Iron Preparations may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron. Alternatively, dolutegravir and oral iron can be taken together with food. Risk D: Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Risk D: Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Risk D: Consider therapy modification

Entacapone: Iron Preparations may decrease the serum concentration of Entacapone. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated. Risk D: Consider therapy modification

Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Preparations. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron preparations. Therapy with oral iron preparations should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex. Risk D: Consider therapy modification

Levodopa: Iron Preparations may decrease the serum concentration of Levodopa. Only applies to oral iron preparations. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated. Risk D: Consider therapy modification

Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. Risk X: Avoid combination

Levothyroxine: Iron Preparations may decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron preparations and levothyroxine by at least 4 hours. Separation of doses is not required with parenterally administered iron preparations or levothyroxine. Risk D: Consider therapy modification

Methyldopa: Iron Preparations may decrease the serum concentration of Methyldopa. Management: Consider separating doses of methyldopa and orally administered iron preparation by 2 or more hours. Monitor for decreased efficacy of methyldopa if an oral iron preparation is initiated/dose increase, or increased efficacy if discontinued/dose decreased. Risk D: Consider therapy modification

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Risk D: Consider therapy modification

Phosphate Supplements: Iron Preparations may decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral iron preparation as possible to minimize the significance of this interaction. Risk D: Consider therapy modification

Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Iron Preparations. Management: Give oral iron products at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Risk D: Consider therapy modification

Quinolones: Iron Preparations may decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron. Risk D: Consider therapy modification

Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Risk D: Consider therapy modification

Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat. Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products. Risk D: Consider therapy modification

Tetracyclines: May decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives. Risk D: Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation. Risk D: Consider therapy modification

Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products. Risk X: Avoid combination

Food Interactions

Cereals, dietary fiber, tea, coffee, eggs, and milk may decrease absorption.

Pregnancy Considerations

Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).

Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).

Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021). Most studies note iron therapy improves maternal hematologic parameters; however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Use of low-dose supplemental iron is recommended for all pregnant patients beginning in the first trimester or first prenatal visit to prevent anemia at term (ACOG 2021).

Ferrous fumarate has been evaluated in multiple studies as an iron supplement or for the treatment of IDA in pregnancy (Abdel Moety 2017; Govindappagari 2019; Karakoc 2022; Lewkowitz 2019; Peña-Rosas 2015; Reveiz 2011; Rogozińska 2021). Ferrous salts are preferred over ferric salts for the oral management of IDA in pregnancy due to better absorption and bioavailability (BSH [Pavord 2020]). Iron supplementation is recommended for 3 months once hemoglobin is within the normal range and at least 6 weeks postpartum to replenish maternal iron stores (BSH [Pavord 2020]; FIGO 2019). Iron supplementation is recommended in addition to use of prenatal vitamins in pregnant patients diagnosed with IDA (ACOG 2021). Enteric-coated and slow/sustained-release preparations may be less effective due to decreased absorption, and use should be avoided (ACOG 2021; BSH [Pavord 2020]).

Breastfeeding Considerations

Iron is present in breast milk.

Endogenous iron concentrations in breast milk vary by postpartum age and are lower than concentrations in the maternal plasma (Dorea 2000; Emmett 1997). Breast milk concentrations of iron are maintained in lactating patients with mild to moderate iron deficiency anemia (IDA), but concentrations decrease if IDA is moderate to severe (El-Farrash 2012) or severe (Kumar 2008).

Ferrous fumarate has been evaluated for the treatment of postpartum IDA (Sultan 2019).

Iron deficiency and IDA are associated with adverse effects in postpartum patients (eg, altered cognition, depression, fatigue), which may influence interactions with the infant. Iron supplementation in the postpartum patient should be initiated as soon as possible following delivery when gestational anemia is a concern (WHO 2016c). The World Health Organization considers ferrous salts used for anemia to be compatible with breastfeeding (WHO 2002). All postpartum patients at risk of gestational anemia (regardless of breastfeeding status) may be given oral iron with or without folic acid for 6 to 12 weeks postpartum to reduce the risk of anemia (WHO 2016c). Oral iron therapy is recommended for postpartum patients with uncorrected anemia at delivery who are hemodynamically stable and are asymptomatic or have only mild symptoms; treatment should continue for at least 3 months (BSH [Pavord 2020]).

Dietary Considerations

May be administered with food to prevent irritation; however, not with cereals, dietary fiber, tea, coffee, eggs, or milk.

Elemental iron content of ferrous fumarate: 33%

Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.

Dietary reference intake (IOM 2001):

0 to 6 months: Adequate intake: 0.27 mg elemental iron/day.

7 to 12 months: RDA: 11 mg elemental iron/day.

1 to 3 years: RDA: 7 mg elemental iron/day.

4 to 8 years: RDA: 10 mg elemental iron/day.

9 to 13 years: RDA: 8 mg elemental iron/day.

14 to 18 years: RDA:

Males: 11 mg elemental iron/day.

Females: 15 mg elemental iron/day.

Pregnant patients: 27 mg elemental iron/day.

Lactating patients: 10 mg elemental iron/day.

19 to 50 years: RDA:

Males: 8 mg elemental iron/day.

Females: 18 mg elemental iron/day.

Pregnant patients: 27 mg elemental iron/day.

Lactating patients: 9 mg elemental iron/day.

≥50 years: 8 mg elemental iron/day.

Monitoring Parameters

Iron-deficiency anemia: Hemoglobin and hematocrit; consider additional tests such as RBC count, RBC indices, serum ferritin, transferrin saturation, total iron-binding capacity, serum iron concentration, and erythrocyte protoporphyrin concentration (CDC 1998)

Cancer and chemotherapy-induced anemia: Serum iron, total iron-binding capacity, transferrin saturation, or ferritin levels (baseline and periodic) (Rizzo 2010)

CKD associated anemia (patients not on dialysis): To monitor response to iron therapy: Hemoglobin, serum ferritin, transferrin saturation (KDIGO 2012)

Reference Range

Anemia:

Hemoglobin, whole blood:

Female: 12 to16 g/dL (SI: 120 to 160 g/L) (ABIM 2023).

Male: 13 to 18 g/dL (SI: 130 to 180 g/L) (ABIM 2023; WHO 2011).

Iron deficiency (ABIM 2023):

Ferritin, serum: Note: Ferritin is an acute phase reactant; levels may be elevated in the presence of inflammation or infection which is independent of iron status (WHO 2020).

Female: 24 to 307 ng/mL (SI: 53.9 to 689.8 picomole/L).

Male: 24 to 336 ng/mL (SI: 53.9 to 755 picomole/L).

Iron, serum: 50 to 150 mcg/dL (SI: 9 to 26.9 micromole/L).

Total iron binding capacity, serum: 250 to 310 mcg/dL (SI: 44.8 to 55.5 micromole/L).

Transferrin saturation: 20% to 50%.

Transferrin, serum: 200 to 400 mg/dL (SI: 24.6 to 49.2 micromole/L).

Chronic kidney disease–associated anemia: To achieve and maintain target hemoglobin for patients with nondialysis-dependent chronic kidney disease, patients with a transferrin saturation (TSAT) ≤30% and a serum ferritin level ≤500 ng/mL (SI: 1,123.5 picomole/L) will often respond to iron supplementation (Gutiérrez 2021; KDIGO 2012).

Mechanism of Action

Replaces iron found in hemoglobin, myoglobin, and enzymes; allows the transportation of oxygen via hemoglobin

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Hematologic response: Oral, parenteral iron salts: ~3 to 10 days

Peak effect: Reticulocytosis: 5 to 10 days; hemoglobin values increase within 2 to 4 weeks

Absorption: Iron is absorbed in the duodenum and upper jejunum; in persons with normal serum iron stores, 10% of an oral dose is absorbed, this is increased to 20% to 30% in persons with inadequate iron stores. Food and achlorhydria will decrease absorption.

Protein binding: To serum transferrin

Excretion: Urine, sweat, sloughing of intestinal mucosa, and menses

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Ferumat | Fumafer | Galfer;
  • (AR) Argentina: Hemofer | Hierro lafedar;
  • (AT) Austria: Ferrobet;
  • (AU) Australia: Apohealth iron | Ferro | Ferroven iron;
  • (BD) Bangladesh: Ferrobolin | Ferrolex | Ferromatt | Ferrous | Fesyrup | Fumarin;
  • (BE) Belgium: Ferrum Hausmann | Ferumat;
  • (BF) Burkina Faso: Ferro denk;
  • (CH) Switzerland: Ferrum Hausmann;
  • (CI) Côte d'Ivoire: Fumarate ferreux tm;
  • (CN) China: Hong hong;
  • (CZ) Czech Republic: Ferronat;
  • (DE) Germany: Eisen floradix | Ferrokapsul | Rulofer N;
  • (DK) Denmark: Livol staerk jern;
  • (DO) Dominican Republic: Ferrubrim | Ircon;
  • (EC) Ecuador: Ferrum Klinge | Fumarato ferroso;
  • (EG) Egypt: Fumiron;
  • (FI) Finland: Erco-fer;
  • (FR) France: Fumafer;
  • (GB) United Kingdom: Ferroess | Ferromate | Ferrous fumara | Fersaday | Fersamal | Galfer | Meterfer | Plancaps;
  • (HR) Croatia: Heferol;
  • (ID) Indonesia: Ferro fumarat | Ferrum Hausmann;
  • (IE) Ireland: Galfer;
  • (JP) Japan: Ferrum mitsubishi | Ferrum nichiiko;
  • (LB) Lebanon: Feosta;
  • (LU) Luxembourg: Ferrum Hausmann | Ferumat;
  • (MA) Morocco: Fumafer;
  • (MX) Mexico: Biofuroso | Croferron | Fernadin | Ferrigen | Ferval | Fum.ferroso valdec | Fumarato ferroso | Gestaferron | Reuffiron;
  • (MY) Malaysia: Dyna Ferrous Fumamarate | Fefur | Ferromed | Ferrotab | Firon | Iron | Trio-Ferrous Fum | Trio-ferrous fumarate | Unifera;
  • (NL) Netherlands: Ferrofumaraat | Ferrofumaraat Actavis | Ferrofumaraat cf;
  • (NO) Norway: Nycoplus neo-fer;
  • (NZ) New Zealand: Aft ferro | Ferro tab;
  • (PE) Peru: Microferrum;
  • (PH) Philippines: Ferro-mar | Microferron;
  • (PK) Pakistan: Feroton | Legafar f;
  • (PR) Puerto Rico: Ferrocite | Hemocyte;
  • (RO) Romania: Heferol;
  • (RU) Russian Federation: Heferol;
  • (SA) Saudi Arabia: Fumafer;
  • (SG) Singapore: Iron;
  • (SI) Slovenia: Heferol;
  • (SK) Slovakia: Ferronat;
  • (TH) Thailand: Fermate | Fersamal | I ron;
  • (TN) Tunisia: Fumafer;
  • (TR) Turkey: Feramat | Fersamal;
  • (TW) Taiwan: Fersamal | Ferumat;
  • (UA) Ukraine: Heferol;
  • (UG) Uganda: Hemosan;
  • (UY) Uruguay: Ferdion | Ferdion Phs;
  • (VE) Venezuela, Bolivarian Republic of: Microferrum;
  • (ZA) South Africa: Nephro fer
  1. Abdel Moety GAF, Ali AM, Fouad R, Ramadan W, Belal DS, Haggag HM. Amino acid chelated iron versus an iron salt in the treatment of iron deficiency anemia with pregnancy: A randomized controlled study. Eur J Obstet Gynecol Reprod Biol. 2017;210:242‐246. doi:10.1016/j.ejogrb.2017.01.003 [PubMed 28073037]
  2. American Academy of Pediatrics Committee on Nutrition. Kleinman RE, Greer FR, eds. Pediatric Nutrition Handbook. 8th ed. Itasca, IL: American Academy of Pediatrics; 2019.
  3. American Board of Internal Medicine (ABIM). Laboratory Test Reference Ranges. Lexi-Drugs. UpToDate Lexidrug. Waltham, MA: UpToDate Inc. https://online.lexi.com. Accessed December 11, 2023.
  4. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. Anemia in pregnancy: ACOG practice bulletin, number 233. Obstet Gynecol. 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477 [PubMed 34293770]
  5. Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 13, 2021.
  6. Baker RD, Greer FR; Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics. 2010;126(5):1040-1050. [PubMed 20923825]
  7. Centers for Disease Control and Prevention (CDC). Recommendations to Prevent and Control Iron Deficiency in the United States. MMWR Recomm Rep. 1998;47(RR-3):1-29. [PubMed 9563847]
  8. Corkins MR, Balint J, Bobo E, et al, eds. The A.S.P.E.N Pediatric Nutrition Support Core Curriculum. 2nd ed. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2015.
  9. Dorea JG. Iron and copper in human milk. Nutrition. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7 [PubMed 10705077]
  10. El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. Pediatr Blood Cancer. 2012;58(2):233-238. doi: 10.1002/pbc.23184. [PubMed 21548016]
  11. Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. Early Hum Dev. 1997;(49)(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0 [PubMed 9363415]
  12. Ferretts (ferrous fumarate) [prescribing information]. Riverton, UT: Pharmics Inc; May 2022.
  13. FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: Iron deficiency anemia in pregnancy. Int J Gynaecol Obstet. 2019;144(3):322‐324. doi:10.1002/ijgo.12740 [PubMed 30710364]
  14. Govindappagari S, Burwick RM. Treatment of iron deficiency anemia in pregnancy with intravenous versus oral iron: systematic review and meta-analysis. Am J Perinatol. 2019;36(4):366-376. doi:10.1055/s-0038-1668555 [PubMed 30121943]
  15. Guideline: Intermittent Iron Supplementation in Preschool and School-Age Children. Geneva: World Health Organization; 2011. [PubMed 24479203]
  16. Gutiérrez O. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. Kidney Int Rep. 2021;6(9):2261-2269. doi:10.1016/j.ekir.2021.05.020 [PubMed 34514189]
  17. Hershko C and Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123(3):326-333. doi:10.1182/blood-2013-10-512624 [PubMed 24215034]
  18. Institute of Medicine, National Research Council, "Iron Deficiency Anemia: Recommended Guidelines for the Prevention, Detection, and Management Among U.S. Children and Women of Childbearing Age," Washington, D.C.: The National Academies Press, 1993.
  19. IOM (Institute of Medicine), Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc, Washington, DC: National Academy Press, 2001.
  20. Karakoc G, Orgul G, Sahin D, Yucel A. Is every other day iron supplementation effective for the treatment of the iron deficiency anemia in pregnancy? J Matern Fetal Neonatal Med. 2022;35(5):832-836. doi:10.1080/14767058.2021.1910666 [PubMed 33866933]
  21. Kazal LA Jr. Prevention of iron deficiency in infants and toddlers. Am Fam Physician. 2002;66(7):1217-1224. [PubMed 12387433]
  22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for anemia in chronic kidney disease (2012). https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed December 11, 2023.
  23. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Inter. 2013;3(suppl):1-150. Available at http://kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf
  24. Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.
  25. Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. Pediatrics. 2008;121(3):e673-e677. doi:10.1542/peds.2007-1986 [PubMed 18310187]
  26. Lewkowitz AK, Gupta A, Simon L, et al. Intravenous compared with oral iron for the treatment of iron-deficiency anemia in pregnancy: a systematic review and meta-analysis. J Perinatol. 2019;39(4):519-532. doi:10.1038/s41372-019-0320-2 [PubMed 30692612]
  27. Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol. 2012;24(2):109-116. [PubMed 22157204]
  28. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126(17):1981-1989. doi:10.1182/blood-2015-05-642223 [PubMed 26289639]
  29. National Academies of Sciences, Engineering, and Medicine 2020. Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop. The National Academies Press; 2020. https://doi.org/10.17226/25841
  30. Oski FA. Iron deficiency in infancy and childhood. N Engl J Med. 1993;329(3):190-193. doi:10.1056/NEJM199307153290308 [PubMed 8515791]
  31. Pavord S, Daru J, Prasannan N, et al. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2020;188(6):819‐830. doi:10.1111/bjh.16221 [PubMed 31578718]
  32. Peña-Rosas JP, De-Regil LM, Garcia-Casal MN, et al. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 201522;(7):CD004736. doi: 10.1002/14651858.CD004736.pub5. [PubMed 26198451]
  33. Powers JM, Buchanan GR, Adix L, Zhang S, Gao A, McCavit TL. Effect of low-dose ferrous sulfate vs iron polysaccharide complex on hemoglobin concentration in young children with nutritional iron-deficiency anemia: a randomized clinical trial. JAMA. 2017;317(22):2297-2304. doi:10.1001/jama.2017.6846 [PubMed 28609534]
  34. Reeves JD, Yip R. Lack of adverse side effects of oral ferrous sulfate therapy in 1-year-old infants. Pediatrics. 1985;75(2):352-355. [PubMed 3969339]
  35. Reveiz L, Gyte GM, Cuervo LG, et al. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2011;(10):CD003094. doi: 10.1002/14651858.CD003094.pub3. [PubMed 21975735]
  36. Rimon E, Kagansky N, Kagansky M, et al, “Are We Giving Too Much Iron? Low-Dose Iron Therapy is Effective in Octogenarians,” Am J Med, 2005, 118(10):1142-7. [PubMed 16194646]
  37. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996-5010. [PubMed 20975064]
  38. Rogozińska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis. Lancet Haematol. 2021;8(7):e503-e512. doi:10.1016/S2352-3026(21)00137-X [PubMed 34171281]
  39. Siu AL; US Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015;163(7):529-36. doi:10.7326/M15-1707 [PubMed 26344176]
  40. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11):e524-e533. doi:10.1016/S2352-3026(17)30182-5 [PubMed 29032957]
  41. Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020;105(5):1232-1239. doi:10.3324/haematol.2019.220830 [PubMed 31413088]
  42. Sultan P, Bampoe S, Shah R, et al. Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221(1):19.e3-29.e3. doi:10.1016/j.ajog.2018.12.016 [PubMed 30578747]
  43. World Health Organization (WHO): Guideline: Daily Iron Supplementation in Adult Women and Adolescent Girls. Geneva, Switzerland: World Health Organization; 2016a. https://www.ncbi.nlm.nih.gov/books/NBK361888/. [PubMed 27195351]
  44. World Health Organization (WHO): Guideline: Daily Iron Supplementation in Infants and Children. Geneva, Switzerland: World Health Organization; 2016b. https://www.ncbi.nlm.nih.gov/books/NBK362032/. [PubMed 27195348]
  45. World Health Organization (WHO). Guideline: Iron Supplementation in Postpartum Women. World Health Organization; 2016c. [PubMed 27583315]
  46. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.
  47. World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22. Published 2011. Accessed December 11, 2023.
  48. World Health Organization (WHO). Serum ferritin concentrations for the assessment of iron status in individuals and populations: technical brief. https://iris.who.int/bitstream/handle/10665/337666/9789240008526-eng.pdf?sequence=1. Published 2020. Accessed December 11, 2023.
  49. Zlotkin S, Arthur P, Antwi KY, Yeung G. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. Pediatrics. 2001;108(3):613-616. doi:10.1542/peds.108.3.613 [PubMed 11533326]
Topic 8442 Version 217.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟